Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. 

 -  2018 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0028-4793 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1808721 [doi] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Anti-Obesity Agents/tu [Therapeutic Use]<br/>*Benzazepines/tu [Therapeutic Use]<br/>*Cardiovascular Diseases/co [Complications]<br/>*Hypoglycemia/ci [Chemically Induced]<br/>*Obesity/dt [Drug Therapy]<br/>*Overweight/dt [Drug Therapy]<br/>*Weight Loss/de [Drug Effects]<br/>Aged<br/>Anti-Obesity Agents/ae [Adverse Effects]<br/>Aortic Valve Insufficiency/ci [Chemically Induced]<br/>Benzazepines/ae [Adverse Effects]<br/>Cardiovascular Diseases/ci [Chemically Induced]<br/>Cardiovascular Diseases/ep [Epidemiology]<br/>Diabetes Mellitus, Type 2/co [Complications]<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Hypertension, Pulmonary/ci [Chemically Induced]<br/>Male<br/>Middle Aged<br/>Obesity/co [Complications]<br/>Overweight/co [Complications]<br/>Risk Factors
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Heart & Vascular Institute
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article